Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...
Pharmaceutical Technology on MSN15d
GSK to acquire Chimagen’s CMG1A46 for autoimmune diseaseGlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...
Richard Staines heard about this new strategy at the Veeva 2019 Commercial and Medical Summit, Europe. GSK’s approach to marketing content has had a major rethink in the last two years ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...
In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...
Shares in GSK opened 1.9-percent lower in London following the results update. Over-the-counter treatment Zantac, known also by its non-commercial name ranitidine, was manufactured by several ...
GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback